

(51) International Patent Classification:  
Not classified(21) International Application Number:  
PCT/US2022/031193(22) International Filing Date:  
26 May 2022 (26.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/193,574 26 May 2021 (26.05.2021) US  
63/270,488 21 October 2021 (21.10.2021) US(71) Applicant: C4 THERAPEUTICS, INC. [US/US]; 490  
Arsenal Way, Suite 200, Watertown, MA 02472 (US).(72) Inventors: NASVESCHUK, Christopher, G.; c/o C4  
Therapeutics, Inc., 490 Arsenal Way, Suite 200, Water-  
town, MA 02472 (US). DUPLESSIS, Martin; c/o C4 Ther-  
apeutics, Inc., 490 Arsenal Way, Suite 200, Watertown,  
MA 02472 (US). AHN, Jae Young; c/o C4 Therapeu-  
tics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA  
02472 (US). HIRD, Alexander, W.; c/o C4 Therapeutics,  
Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472  
(US). MICHAEL, Ryan, E.; c/o C4 Therapeutics, Inc.,490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).  
**LAZARSKI, Kiel**; c/o C4 Therapeutics, Inc., 490 Arse-  
nal Way, Suite 200, Watertown, MA 02472 (US). **LIANG,**  
**Yanke**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite  
200, Watertown, MA 02472 (US). **JAESCHKE, Georg**;  
c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124,  
4070 Basel (CH). **RICCI, Antonio**; c/o F. Hoffmann-La  
Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **GO-**  
**ERGLER, Annick**; c/o F. Hoffmann-La Roche AG, Gren-  
zacherstrasse 124, 4070 Basel (CH). **RUEHER, Daniel**; c/  
o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070  
Basel (CH).(74) Agent: BELLOWS, Brent, R. et al.; Knowles Intellectual  
Property Strategies, LLC, 400 Perimeter Center Terrace,  
Suite 200, Atlanta, GA 30346 (US).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS




FIG. 2A

(57) Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*